Page last updated: 2024-12-08
ym17e
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
YM17E: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 180289 |
| CHEMBL ID | 4301889 |
| SCHEMBL ID | 9263610 |
| MeSH ID | M0214806 |
Synonyms (11)
| Synonym |
|---|
| ym17e |
| SCHEMBL9263610 |
| HY-101627 |
| CS-6836 |
| 124900-72-7 |
| 1,1'-(1,3-phenylenebis(methylene))bis(1-cycloheptyl-3-(4-(dimethylamino)phenyl)urea) |
| F81717 |
| MS-30977 |
| CHEMBL4301889 |
| 1-cycloheptyl-1-[[3-[[cycloheptyl-[[4-(dimethylamino)phenyl]carbamoyl]amino]methyl]phenyl]methyl]-3-[4-(dimethylamino)phenyl]urea |
| AKOS040740594 |
Research Excerpts
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| "We conducted a single and repeat oral dose study of YM17E, a novel inhibitor of acyl coenzyme A (CoA): cholesterol acyltransferase, in healthy male volunteers to evaluate the pharmacokinetic profile, tolerability and effect of the drug on serum cholesterol." | ( Pharmacokinetic properties of YM17E, an inhibitor of acyl coenzyme A: cholesterol acyl transferase, and serum cholesterol levels in healthy volunteers. Goto, Y; Higuchi, S; Kikawa, Y; Maezawa, K; Nakata, M; Nakaya, N; Tsunoo, M; Uchida, T; Usui, T; Watanabe, T, 1997) | 0.3 |
Bioavailability
The relationship between bioavailability and the serum cholesterol-lowering effect of YM17E, an ACAT inhibitor was investigated. Bioavailability of Ym17E was 5-9% at oral doses of 3-30 mg/kg in rat.
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " When YM17E was administered at the same total dosage but divided into 5 daily administrations, the incidence of diarrhea was significantly reduced while its cholesterol lowering effect became stronger." | ( Pharmacological properties of YM17E, an acyl-CoA:cholesterol acyltransferase inhibitor, and diarrheal effect in beagle dogs. Iizumi, Y; Ito, N; Kakuta, H; Kashiwa, M; Kiriyama, T; Masuyama, Y; Matsuda, K; Miyauchi, H; Naganuma, S; Takenaka, T; Terada, M; Uchida, T, 1997) | 0.3 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (9)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (10.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (90.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||